This strategic move brings stability to Embecta, addressing challenges faced since its spin-off from Becton Dickinson & Co.

The acquisition brings in the Aidaptus auto-injector platform and related intellectual property.

Alerje founder Javier Evelyn’s mobile auto-injector platform was recently acquired by SemPresto.

EMBC to acquire Owen Mumford for up to $199.4M, aiming to expand beyond diabetes into high-value drug delivery and boost long ...

The acquisition positions Embecta to enter the fast-growing drug-delivery device market and accelerate its shift to a broader ...

Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic ...

Diabetes care firm Embecta reached an agreement to buy Owen Mumford Holdings for up to 150 million pounds ($201 million) the ...

Embecta Corp. ("Embecta") (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement ...

This reflects the confidence pharmaceutical innovators place in Pyramid’s expanded state-of-the-art facility to deliver ...

Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as “Zydus”), an innovation-led global ...

Embecta hits multi-year lows on GLP-1 fears, but offers 6%+ yield and deep value. Read the latest analysis on the stock and ...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EURneffy-t ...